Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00887926 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00887926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00887926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2009
Completion date
August 31, 2010
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid leukemia